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Inhibition of NOX2 reduces locomotor
impairment, inflammation, and oxidative
stress after spinal cord injury
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Abstract
Background: Spinal cord injury (SCI) results in the activation of the NADPH oxidase (NOX) enzyme, inducing
production of reactive oxygen species (ROS). We hypothesized that the NOX2 isoform plays an integral role in
post-SCI inflammation and functional deficits.
Methods: Moderate spinal cord contusion injury was performed in adult male mice, and flow cytometry, western
blot, and immunohistochemistry were used to assess NOX2 activity and expression, inflammation, and M1/M2
microglia/macrophage polarization from 1 to 28 days after injury. The NOX2-specific inhibitor, gp91ds-tat, was
injected into the intrathecal space immediately after impact. The Basso Mouse Scale (BMS) was used to assess
locomotor function at 24 h post-injury and weekly thereafter.
Results: Our findings show that gp91ds-tat treatment significantly improved functional recovery through 28 days
post-injury and reduced inflammatory cell concentrations in the injured spinal cord at 24 h and 7 days post-injury. In
addition, a number of oxidative stress markers were reduced in expression at 24 h after gp91ds-tat treatment, which
was accompanied by a reduction in M1 polarization marker expression.
Conclusion: Based on our findings, we now conclude that inhibition of NOX2 significantly improves outcome
after SCI, most likely via acute reductions in oxidative stress and inflammation. NOX2 inhibition may therefore
have true potential as a therapy after SCI.
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Background
Spinal cord injury (SCI) is followed by an acute but
long-lasting inflammatory response, marked by invasion
of blood-borne cells and activation of endogenous cells
and a marked increase in reactive oxygen species (ROS)
production. Neutrophils are the first cells to respond,
invading the spinal cord within minutes to hours and
populating the injured tissue for days [1]. Following this
response is a macrophage/microglial response that typ-
ically peaks within 4–7 days [2]. Both of these cell types
express the NADPH oxidase (NOX) 2 enzyme, which is
a primary producer of ROS in the spinal cord after
injury.
Research has shown that this macrophage/microglia
response is not homogenous, and both cell types can be
polarized into pro-inflammatory M1 cells or anti-
inflammatory M2 cells [3]. Early work demonstrated
that, after SCI, the M1/M2 ratio is roughly equal
acutely after injury but shifts to an M1 dominant re-
sponse within a few days [4]. It is currently unclear
what signals result in this M1/M2 shift, although some
research has suggested that the NOX enzyme may play
a role in not only this polarization [5] but also general
inflammatory responses and oxidative stress.
The NOX enzyme complex is a primary source of
ROS, with seven currently known family members, in-
cluding NOX2 [6]. The enzyme functions by transfer-
ring electrons from NADPH inside the cell, across the
membrane, and then to extracellular oxygen, generating a
superoxide. Components of the NOX2 enzyme, including
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the enzymatic core, gp91PHOX, and membrane-bound
companion protein, p22PHOX, are elevated after SCI [7–11],
and NOX activity is upregulated for at least 6 months
post-injury [9].
The NOX2-specific inhibitor, gp91ds-tat, a 20-amino
acid peptide that interferes with the assembly of activated
NOX2, has been used in research for a number of differ-
ent disease states, both in vitro and in vivo designs. In
vitro, gp91ds-tat effectively reduces the release of ROS
from activated microglia [12]. Previously, we found that
systemic administration of gp91ds-tat reduced both oxida-
tive stress and cytokine production acutely after SCI [11].
In addition, gp91ds-tat was found to be neuroprotective in
a traumatic brain injury model [13].
The aim of the current paper was to explore the ef-
fect of specific inhibition of NOX2 on oxidative stress,
inflammation, and function after SCI. We now show that
inhibition of NOX2 reduces post-injury inflammation and
improves locomotor recovery in mice. In addition, we
show that NOX2 inhibition shifts microglial/macrophage
polarization toward the M2 phenotype, which may have
significant neuroprotective effects in the injured spinal
cord.
Methods
Animal handling and surgical methods
Adult male C57Bl6 mice were utilized in all experi-
ments (20–25 g, Taconic Farms, Derwood, MD). Mice
were group housed and received food and water ad
libitum with a 12:12 h light cycle. A total of 111 male
mice were used for this study; 13 mice were removed
from the study due to post-surgical complications. All
experiments complied fully with the principles set forth
in the “Guide for the Care and Use of Laboratory Animals”
and were approved by the Uniformed Services University
IACUC.
All subjects undergoing surgery received isoflurane
(Primal Healthcare, Andhra Pradesh, India). Mice received
a laminectomy, followed by a contusion simulating mod-
erate SCI using the Infinite Horizons Impactor (50 kdyn;
Precision Systems and Instrumentation, Fairfax Station,
VA). Mice were immediately given an intrathecal injection
of either gp91ds-tat or scrambled ds-tat (AnaSpec, Inc.,
Fremont, CA) diluted to 50 μM in saline in a 5 μl volume
at the lesion epicenter. After expelling the liquid, the
needle was held under the dura for 30 s prior to re-
moval. The incision was then closed, and animals were
maintained on heating pads until mice regained move-
ment. Acetaminophen (Children’s Tylenol, 200 mg/kg)
was added to drinking water for 72 h post-injury.
Manual bladder expression was performed daily until
normal bladder expression returned. Naïve mice did
not undergo surgery or receive isoflurane.
Functional testing
The Basso Mouse Scale (BMS) was used to rate loco-
motor function and recovery. Injured mice in recovery
were scored in seven categories including ankle move-
ment, plantar placement, stepping, coordination, paw pos-
ition, trunk instability, and tail position. Mice (n = 9/group)
from the 28-day time point group were observed at 24 h
by two investigators blinded to the treatment group and
then weekly post-injury.
Immunohistochemistry
At 2 h (n = 4 gp91ds-tat, 3 scrambled ds-tat), 24 h (n = 4
gp91ds-tat, 4 scrambled ds-tat), 7 days (n = 3 gp91ds-tat, 4
scrambled ds-tat), and 28 days (n = 4 gp91ds-tat, 4 scram-
bled ds-tat), injured or naïve (n = 4) mice were anesthe-
tized (Euthasol, 0.22 ml/kg, IP) and perfused with 100 ml
of 0.9 % sterile saline, followed by 300 ml of 10 % buffered
formalin phosphate (Fisher Scientific, Fair Lawn, NJ). A 5-
mm spinal cord segment, 2.5 mm caudal and 2.5 mm
rostral to the injury site, was extracted. Spinal cords were
kept in formalin for 24 h and then transferred to a 30 %
sucrose solution. Spinal cords were then cut into 20-μm
axial sections. Standard fluorescent immunohistochemis-
try was performed with primary antibodies that had been
previously characterized in the laboratory [11, 12], includ-
ing Iba1 (1:100, Wako), CD86 (1:200, Abcam), Mannose
Receptor/CD206 (1:50, Abcam), and 3NT (1:5, Abcam).
Alexa-Fluor secondary antibodies (Invitrogen) were used
for visualization. Slides were coverslipped using mounting
media containing DAPI to counterstain for nuclei (Vector
Labs, Burlingame, CA).
Immunofluorescence was detected and photographed
in the dorsal column region within the 5-mm region of
interest using an Olympus DP72 microscope with Olym-
pus cellSens microscopy software (Olympus, Center Val-
ley, PA) or NanoZoomer Digital Pathology system
(Hamamatsu Photonics, K.K., Japan). For 3NT immuno-
histochemistry, fluorescent immunohistochemistry was
quantified as previously described using pixel density
measurement in Scion Image [14]. For all other immu-
nohistochemistries, images were qualitatively evaluated
for comparison to flow cytometry and western blotting
results. For all stains, at least five sections taken from
regular intervals within the 5-mm region of interest were
evaluated.
Western blot
At 24 h (n = 4 gp91ds-tat, 4 scrambled ds-tat), 7 days (n
= 6 gp91ds-tat, 5 scrambled ds-tat), and 28 days (n = 3
gp91ds-tat, 3 scrambled ds-tat) post-injury or after no
intervention (naïve, n = 8), mice were euthanized and tis-
sue was flushed with 100 ml of 0.9 % sodium chloride. A
5-mm spinal cord segment, 2.5 mm rostral and 2.5 mm
caudal to the lesion epicenter, was collected and protein
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extracted with RIPA (1×) buffer (Thermo Scientific,
Rockford, IL). Aliquots of 25 μg were used for western
analysis using the following primary antibodies: CD86
(Abcam, 1:250), CD206 (Abcam, 1:500), iNOS (Cell
Signaling Technology, 1:200), and phospho-p47PHOX
(p-p47; Sigma, 1:250). Immune complexes were de-
tected with appropriate secondary antibodies and
chemiluminescence reagents (Pierce, Rockford, IL).
GAPDH was used as a control for gel loading and pro-
tein transfer. ImageJ software was used to quantify
bands.
Oxyblot
All samples from the western blot experiments were
also used for oxyblot experiments. Millipore OxyBlot
Protein Oxidation Detection Kit (Temecula, CA) was
used according to the manufacturer’s instructions. β-
actin (Abcam) was used as control for gel loading and
protein transfer. ImageJ software was used to quantify
resultant bands.
Flow cytometry
A 5-mm spinal cord segment, 2.5 mm caudal and 2.5 mm
rostral to the injury site, was processed for flow cytometry
at 24 h (n = 4 gp91ds-tat, 4 scrambled ds-tat) and 7 days
(n = 8 gp91ds-tat, 9 scrambled ds-tat) post-injury, follow-
ing a perfusion with 100 ml of 0.9 % saline. Cells were
isolated using a 70, 37, 30 % Optiprep gradient (Axis-
Shield, Wesbury, NY) in 1× HBSS solution. Cells were
blocked with TruStain fcX (1:200 BioLegend, San Diego,
CA), and macrophages, microglia, lymphocytes, neutro-
phils, and dendritic cell populations were immunolabled
with PE CD11b (1:200 eBioscience Inc., San Diego,
CA), APC/Cy7 CD45(1:500, BioLegend, San Diego,
CA), APC CD3ε (1:200, BioLegend), and FITC GR-
1(1:2000 BioLegend, San Diego, CA) in flow cytometry
staining buffer. Sytox Blue was used as a dead cell
marker (1:1000 Molecular Probes, Inc. Eugene, OR).
OneComp eBeads (one drop per sample, eBioscience
Inc., San Diego, CA) were used in place of tissue as
marker controls, while tissue was used for unstained
control for analysis purposes. Corresponding isotype
controls were used per fluorochrome. Populations of
interest were gated on, and at least 200,000 cells were
collected for each sample. Data was analyzed using
FlowJo software (FlowJo, LLC, Ashland, OR).
Statistics
Quantitative data are presented as mean ± standard error
of the mean. BMS and BMS subscore data were obtained
by two blinded investigators and analyzed using repeated
measures ANOVA with Bonferroni’s multiple compari-
sons test. All other quantitative data were analyzed using
unpaired t test or one-way ANOVA as appropriate. All
statistical tests were performed using the GraphPad Prism
Program, Version 6.03 for Windows (GraphPad Software,
San Diego, CA). A p value <0.05 was considered statisti-
cally significant.
Results
NOX2 inhibition improves locomotor function
The BMS score provides a general locomotion score
reflecting all four limbs, while the subscore reflects more
distinct measures of locomotor control, such as plantar
stepping, coordination, and paw position. Although both
animal groups exhibited a gradual recovery, mice treated
with gp91ds-tat showed an overall improvement with a
significant improvement at 14- and 28-day time points
compared to those treated with scrambled ds-tat (Fig. 1a).
Furthermore, gp91ds-tat-treated mice demonstrated a re-
covery in more fine motor control, as shown in the BMS
subscore, after 7 days with a significant improvement at
14 days (Fig. 1b). Scrambled ds-tat-treated mice only
demonstrated an increase in BMS subscore at 28 days
post-injury.
Fig. 1 Inhibition of NOX2 improves motor function. Gross hindlimb motor function was scored using the BMS (a), with further analysis of hindpaw
function with the BMS subscore (b). Mice were tested at days 1, 7, 14, 21, and 28 post-injury. Those treated with gp91ds-tat showed significant
increases in BMS score and BMS subscore at 7 days; this improvement was sustained through 28 days in the BMS score. Points represent mean
± SEM. N = 9/group. *p < 0.05, repeated measures ANOVA
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NOX2 inhibition reduces acute oxidative stress
An oxyblot assay, which detects carbonylated proteins,
was performed to measure the overall oxidative stress
present in the injured tissue (Fig. 2a). While injury re-
sulted in an increase in carbonylated proteins at 24 h,
carbonylation of proteins was significantly reduced in
tissue that received gp91ds-tat in comparison to the
scrambled ds-tat (Fig. 2b).
To further investigate oxidative stress, tissue was stained
with an antibody against 3NT, a marker for nitrotyrosine-
containing proteins (Fig. 2c, d). At 24 h post-injury,
scrambled ds-tat-treated tissue demonstrated elevated
3NT immunostaining in both white and gray matters in
comparison to naïve tissue. Qualitatively, gp91ds-tat-
treated spinal cord showed less staining at both 24 h and
7 days post-injury. At 28 days post-injury, residual expres-
sion in the lesion site was still observed in both groups,
although reduced in comparison to earlier time points.
When the immunostain was quantified, no significant
differences were observed between the gp91ds-tat and
Fig. 2 Acute inhibition of NOX2 reduces markers of oxidative stress. OxyBlot Protein Oxidation assay was used to detect protein carbonylation in
naïve (n = 8), scrambled ds-tat- (n = 4), and gp91ds-tat-treated mice (n = 4) at 24 h post-injury (a). Densitometry demonstrated a significant increase in
protein carbonylation in scrambled ds-tat-treated mice, which was significantly reduced to naïve levels with gp91ds-tat treatment (b). At these same
time points, spinal cord tissue was immunolabeled for 3-nitrotyrosine (green), a marker of nitrosylated protein (scrambled ds-tat: n = 4/time
point; gp91ds-tat: n = 4/24 h, 3/7 days; 4/28 days). DAPI nuclear stain is shown in blue. Naïve (n = 4) tissue is shown in c. Qualitative analysis
shows that scrambled ds-tat-treated tissue had elevated 3NT immunolabeling in comparison to naïve tissue, primarily in gray matter (d). This
elevation grew through 7 days and was lessened at 28 days. Treatment with gp91ds-tat appeared to reduce this immunolabeling at all time
points. Bar = 100 μm. *p < 0.05 vs naïve; +p < 0.05 vs scrambled; one-way ANOVA with Tukey’s post-test. Bars represent mean ± SEM
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scrambled ds-tat groups at any time point, although a
trend toward significance was seen at all time points, with
slight reductions in 3NT quantity in the white matter.
Finally, to determine whether NOX2 inhibition may
interfere with NOX2 activity, phosphorylation of the
NOX2 component p47PHOX was assessed. Gp91ds-tat
interferes with the activation of the NOX2 enzyme by
blocking binding of phosphorylated p47PHOX with the
gp91PHOX subunit [6]. The expression of this enzyme is
dependent on a feed-forward cycle, wherein ROS pro-
duction by NOX2 can activate downstream signal
transduction pathways that increase NOX2 component
expression, including p47PHOX. Therefore, expression
of phosphorylated p47PHOX was assessed using western
blotting (Fig. 3b). Phosphorylation of p47PHOX was
markedly elevated at 24 h post-injury, with no signifi-
cant difference between groups. However, by 7 days
post-injury, phosphorylation of p47PHOX was signifi-
cantly reduced in the gp91ds-tat-treated group, suggest-
ing that activity of this enzyme was reduced at this time
point, despite the lack of acute reduction (Fig. 3a).
NOX2 inhibition reduces inflammatory cell populations in
the injured spinal cord
In order to determine the mechanism behind the im-
proved functional outcome and determine the influence
of reduced NOX2 activity and oxidative stress, flow
cytometry was used to assess the percentages of macro-
phage, microglia, lymphocyte, and neutrophil populations
at 24 h and 7 days post-injury. At 24 h post-injury,
gp91ds-tat treatment was found to significantly reduce the
neutrophil population (CD45+/GR-1+; Fig. 4b). By
7 days, macrophage/microglia (CD45+/CD11b+/GR-1−;
Fig. 5b) was significantly reduced by gp91ds-tat adminis-
tration. Neutrophils had a trend toward lower expression,
although no significance was found (Fig. 5d). Further sep-
aration of the macrophage/microglia population by divid-
ing this group into CD45high (macrophage) and CD45low
(microglia) expression groups demonstrated that at 7 days
post-injury, there was a greater proportion of microglia
than macrophages in the injured spinal cord, and that this
population demonstrated a greater response to gp91ds-tat
treatment (Fig. 6b). No significant difference in T cell
population (CD45+/CD3+; Fig. 5f) was noted between
treatment groups.
We next confirmed these flow cytometry results using
immunohistochemistry. Immunostaining demonstrated a
marked elevation in Iba1 staining in scrambled-tat-treated
tissue from 24 h to 7 days post-injury (Fig. 7a–d). In tissue
that had received gp91ds-tat administration, this elevation
was not observed, and Iba1 staining was relatively low
throughout the study.
NOX2 inhibition shifts microglia/macrophage polarization
As gp91ds-tat was found to shift the inflammatory re-
sponse, it was unclear if this had any effect on micro-
glia/macrophage polarization. Previous studies have
shown that NOX2 inhibition can alter polarization
states [5]. We therefore assessed polarization markers
in the spinal cord using flow cytometry, immunohis-
tochemistry, and western blotting.
At 7 days post-injury, the M2 marker CD206 showed a
significant increase with gp91ds-tat treatment compared
to scrambled ds-tat, using both flow cytometry (Fig. 8)
and western blotting (Fig. 9a).
Western blot data from 24 h post-injury revealed that
expression of the M1 marker CD86 was significantly re-
duced in the gp91ds-tat group in comparison to the
scrambled ds-tat group (Fig. 9b). However, expression
of this protein then returned to levels demonstrated in
the scrambled ds-tat-treated group by 7 and 28 days
Fig. 3 Acute inhibition of NOX2 using gp91ds-tat reduces p47PHOX expression and/or phosphorylation. Phosphorylated p47PHOX (p-p47) and GAPDH
were evaluated at 24 h, 7 days, and 28 days post-injury in naïve (N; n = 8), scrambled ds-tat- (S; n = 4/24 h; 6/7 days; 3/28 days), and gp91ds-tat-treated
samples (G; n = 4/24 h; 5/7 days; 3/28 days). Bands were observed at 47 and 38 kDa, respectively, in a representative western blot (a). Pixel densitometry
for p-p47PHOX (b) showed significant induction of phosphorylation of p47PHOX at 24 h. NOX2 inhibition reduced p-p47PHOX levels at 7 days to a point
that was not significantly greater than sham. **p < 0.01 vs naïve. +p < 0.01 vs scrambled; one-way ANOVA with Tukey’s post-test. Bars
represent mean ± SEM
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Fig. 4 Acute inhibition of NOX2 reduces neutrophil populations by 24 h post-injury. Neutrophils were characterized as alive, CD45+/CD11b+/GR-1+
population (a). b Quantitation shows that gp91ds-tat treatment significantly reduced this population. *p < 0.05 vs scrambled ds-tat, Student’s
t test. Bars represent mean ± SEM
Fig. 5 Acute NOX2 inhibition reduces inflammatory response by 7 days post-injury. All listed cell types were under a live CD45+ gate. Microglia/
macrophage were further isolated as CD11b+Gr-1− (a), neutrophils as CD11b+Gr-1+ (c), and T cells as CD3+ (e). The first column in each row
indicates an isotype control. Quantitation shows that gp91ds-tat treatment significantly reduced the macrophage/microglia (b) and neutrophil (d)
populations but had no significant effect on the T cell population (f). *p < 0.05 vs scrambled ds-tat, Student’s t test. Bars represent mean ± SEM
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post-injury. An additional M1 marker, iNOS, demon-
strated significantly reduced expression at 7 days post-
injury, with no significant difference between groups at
24 h and 28 days (Fig. 9c).
Discussion
We now show that a single acute central administration
of the NOX2 inhibitor gp91ds-tat led to significant im-
provements in a number of measures of recovery after
moderate SCI. Recovery was seen on both the functional
and cellular levels, including increases in BMS score and
subscore, reductions in measures of oxidative stress, and
reduced inflammatory cell presence through 7 days post-
injury. Despite the observation that this single acute
treatment did not induce inflammatory effects beyond
7 days, functional improvement continued through at
least 28 days, indicating the importance of acute and
subacute interventions.
Although the NADPH complex enzyme group encom-
passes several different NOX and DUOX complexes, our
use of gp91ds-tat was specific to the NOX2 isoform.
This peptide contains a sequence that mimics gp91PHOX
and binds to phosphorylated p47PHOX [15]. This peptide
then blocks ROS production specifically by the NOX2
isoform, having no effect on NOX1 or 4 [16]. In vitro,
gp91ds-tat has been shown to block the assembly of the
NOX2 enzyme [17]. In vivo, gp91ds-tat reduced neur-
onal death in a brain injury model when administered as
a single pre-treatment dose [13].
A number of NOX inhibitors have been used in the
past. These include apocynin, which interferes with the
assembly of the active NOX enzyme [18], and dipheny-
leneiodonium (DPI), which directly blocks the catalytic
activity of NOX (and other flavoprotein-containing
enzymes) [19]. Apocynin has been shown to reduce oxi-
dative stress in the central nervous system during
conditions including sepsis [20] and brain injury [13, 21],
providing significant neuroprotection. More importantly,
apocynin administration following SCI in rats significantly
reduced a number of inflammatory and oxidative stress
markers, including neutrophil invasion, nitrotyrosine pro-
duction, and pro-inflammatory cytokine expression [22].
Further, DPI administration reduced oligodendrocyte and
oligodendrocyte precursor death in lipopolysaccharide
induced inflammation models [23]. More importantly, we
have shown that DPI administration following SCI re-
duces lesion volume and post-injury inflammation [9].
However, DPI and apocynin have been found to have
numerous non-specific effects and can act on enzymes
beyond the NOX family that contain flavoproteins [24].
Fig. 6 Acute NOX2 inhibition specifically targets microglia. Flow cytometry was used to analyze macrophage and microglia populations in the
injured region. Live cells were first gated on and further differentiated based on CD11b+ and CD45+. CD45 high, macrophages, and CD45 low,
microglia, were arbitrarily chosen by a researcher blinded to study (a). Quantitation demonstrated no significant difference in macrophages at
7 days post-injury between scrambled ds-tat- and gp91ds-tat-treated tissue. Microglia, on the other hand, showed a significant decrease in tissue
treated with gp91ds-tat compared to scrambled ds-tat (b). *p < 0.05 vs scrambled ds-tat, Student’s t test. Bars represent mean ± SEM
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While picomolar concentrations have been shown to re-
duce these flavoprotein effects [25], these drugs are still
not specific for any particular NOX isoform. In contrast,
we now show that specific and acute inhibition of the
NOX2 isoform can reduce inflammation in both the
acute and subacute periods, leading to long-term func-
tional improvement.
The functional improvement observed was measured
using both the BMS and the BMS subscore, suggesting
improvements in both gross and fine motor skills. These
improvements first became significant at 14 days post-
injury, although a trend was observed as early as 7 days,
which is the time point at which significant differences
in several markers of oxidative stress and inflammation
Fig. 7 Acute NOX2 inhibition reduces microglia/macrophage presence in injured spinal cord tissue. Gp91ds-tat- and scrambled ds-tat-treated
tissue at 24 h (a, b; n = 4/group) and 7 days (c, d; n = 3 gp91ds-tat, 4 scrambled ds-tat) post-injury was stained for the pan microglia/macrophage
marker Iba1 (red). DAPI nuclear stain is shown in blue. At 24 h post-injury, the scrambled ds-tat-treated tissue (a) have a greater number of activated
microglia compared to gp91ds-tat-treated tissue as seen in ×10 magnification (b). The activated morphology includes a more amoeboid body with
retracted dendrites (which can be better observed in the higher magnification inset image (×20)). At the same time point, the microglia present in
gp91ds-tat tissue have long processes and smaller bodies. This difference is greater at the 7-day time point when microglia are at their peak (c, d). The
gp91ds-tat-treated microglia at 7 days (×20) are activated, but the number are still downregulated compared to those treated with scrambled-tat.
Lower magnification and high-magnification images shown; bar (×20) = 50 μm; bar (×10) = 100 μm
Fig. 8 Acute NOX2 inhibition increases the M2 marker CD206 by 7 days post-injury. Cells were gated on live CD45+CD11b+Gr-1−CD206+ population (a).
Quantitation shows that gp91ds-tat treatment significantly increased the CD206 population (b). *p < 0.05 vs scrambled ds-tat, Student’s t test. Bars
represent mean ± SEM
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were observed. Despite the fact that no significant differ-
ence in oxidative stress marker or inflammation was
observed at 28 days post-injury, functional improvement
continued through 28 days, suggesting that acute inhib-
ition of NOX2 was sufficient to result in sustained func-
tional changes. However, it is important to note that by
21–28 days post-injury, the significance in the BMS
subscore between the gp91ds-tat- and scrambled ds-tat-
treated groups was lost, suggesting that sustained or
even delayed administration of treatment may have fur-
ther benefits.
A number of studies have shown that NOX isoforms are
upregulated after central nervous system injury, including
brain injury [12, 13] and SCI [7–11], and may contribute
to post-injury oxidative stress. This study adds to that
literature, demonstrating elevated protein carbonylation
and nitrosylation in combination with elevated expression
and/or phosphorylation of p47PHOX. Phosphorylation of
the p47PHOX subcomponent results in unmasking of
PHOX-binding domains in the protein, allowing for
assembly and activation of the enzyme [26]. Interestingly,
we found the greatest elevation in protein expression of
the NOX2 component at 24 h after injury, with expression
and phosphorylation reduced by 7 days and returning to
baseline levels by 28 days. This is in contrast to our previ-
ous work, wherein gene and protein expression of NOX2
components gp91PHOX and p22PHOX as well as NOX ac-
tivity were elevated for months after injury [9]. However,
the extended expression profile was determined in a rat
model of SCI; it is likely that the mouse model used in the
Fig. 9 Acute inhibition of NOX2 using gp91ds-tat alters microglia/macrophage polarization marker expression. Protein samples (25 μg) were probed
for CD206, iNOS, CD86, and GAPDH at 24 h, 7 days, and 28 days post-injury in naïve (n = 8), scrambled ds-tat- (n = 4/24 h; 6/7 days; 3/28 days), and
gp91ds-tat-treated samples (n = 4/24 h; 5/7 days; 3/28 days). Pixel densitometry for CD206 (a), CD86 (b), and iNOS (c) showed significant alteration with
gp91ds-tat treatment in comparison to scrambled ds-tat treatment. The M2 marker CD206 was elevated in both groups at 24 h in comparison to naïve,
but remained elevated only in the gp91ds-tat-treated group at 7 days post-injury, before returning to baseline levels by 28 days. In contrast, at 24 h,
the inhibition of NOX2 significantly reduced the expression of the M1 marker CD86, although by 7 and 28 days, no significant difference was observed
between groups. Finally, a second M1 marker, iNOS, was elevated in both groups at 24 h post-injury, and gp91ds-tat treatment only prevented this
induction by 7 days post-injury. *p < 0.05 vs naïve; +p < 0.05 vs scrambled; one-way ANOVA with Tukey’s post-test. Bars represent mean ± SEM
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current study demonstrates a different NOX expression
and activity profile. Future research will continue to ex-
plore these differences. Regardless, the evidence indicates
that NOX2 is active for at least 7 days post-injury, suggest-
ing that a delayed treatment approach may be efficacious
in this model and others.
Concurrently or following this alteration in oxidative
stress status, we observed a significant reduction in
post-injury inflammation, including acute and subacute
reductions in neutrophil invasion and subacute reduc-
tions in macrophage/microglial populations with gp91ds-
tat administration. Interestingly, microglial populations,
defined by low expression of the CD45 marker, were most
affected by gp91ds-tat administration. This is likely due
to the local rather than systemic administration of the
NOX2 inhibitor. Systemic administration of apocynin, a
non-specific NOX inhibitor, has been shown to similarly
reduce inflammatory responses, but without specific effects
on microglia [22]. Further, this study demonstrated that
apocynin administration reduced adhesion molecule ex-
pression, which may provide an explanation for the reduc-
tion in neutrophil invasion observed with local spinal cord
injection of gp91ds-tat. In addition, while analysis with
both flow cytometry and immunohistochemistry demon-
strated no significant difference in microglia/macro-
phage presence at 24 h, qualitative analysis suggested a
morphological change, with fewer “activated” macro-
phages/microglia at this time point in gp91ds-tat-
treated tissue. Activated microglia/macrophages are
known to demonstrate an amoeboid structure with
retracted dendrites, which was seen in tissue that re-
ceived the scrambled ds-tat control treatment; gp91ds-
tat-treated tissue demonstrated a qualitatively greater
presence of ramified cells, with small cell bodies and long
thin processes [27].
To further explore the phenotype of the affected mac-
rophages and microglia, cellular polarization was inves-
tigated. In 2009, Kigerl et al. [4] demonstrated that
there is a balance of M1 and M2 markers acutely after
injury that is followed by an increase in the M1:M2
ratio in the subacute period. Our data support these
findings, with elevated M1 and M2 marker expression
at acute time points and a shift toward M1 dominance
by 7 days post-injury. Gp91ds-tat administration appears
to limit this shift, however, reducing the decline of the M2
polarization marker at 7 days post-injury (Figs. 8 and 9a)
and reducing M1 markers at 1 or 7 days post-injury
(Fig. 9b, c). The influence of NOX2 inhibition on M1
marker expression was somewhat variable, with acute
effects observed in the CD86 marker and subacute effects
in the iNOS marker; this may reflect a variability in
polarization phenotypes over time. Future research is
needed to more precisely identify the influence of NOX
inhibition on polarization. Further, it should be noted
that M1 and M2 marker expression in the gp91ds-tat-
treated group had returned to scrambled ds-tat-treated
group levels by 28 days post-injury, suggesting that a
single acute administration is insufficient to retain a
long-lasting alteration in polarization.
Despite this, we, and others, have now shown that acute
alterations in microglial polarization and NOX activity
can influence each other. Administration of the M2-
polarizing cytokine IL4 induced a reduction in NOX2
expression by 24 h [28]. Inhibition of NOX activity, via
knockout of p47PHOX and gp91PHOX or administration
of apocynin, on the other hand, significantly reduced
M1 polarization and shifted microglia in LPS-treated
brain tissue to an M2 polarization state [5]. This shift
was accompanied by a reduction in pro-inflammatory
cytokines and Iba1 immunolabeling. These results are
supported by our current study and extended to the
spinal cord trauma field, demonstrating that inhibition of
the NOX2 isoform specifically reduces M1 polarization,
increases M2 polarization, and reduces a number of pro-
inflammatory markers.
In conclusion, these data demonstrate that a single acute
NOX2-specific inhibition can have dramatic effects on
oxidative stress, inflammation, and microglial polarization
following SCI, and that these effects significantly improve
post-injury functional recovery. NOX2, therefore, plays an
integral role in post-injury inflammation, and specific
activity on this enzyme can be targeted in order to help
avoid non-target effects. Despite the marked alterations, we
did observe a return to untreated injury levels in many of
our outcome measures by 1 month post-injury, suggesting
that work remains to elucidate the appropriate treatment
approach in order for this therapy to be considered for fur-
ther development and clinical use.
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